期刊文献+

HER2的表达及其分子影像的研究进展

Research and development of HER2 expression molecular imaging
原文传递
导出
摘要 人表皮生长因子受体2(HER2)是一种具有酪氨酸激酶活性的跨膜受体,同时也是一种高表达于各种癌细胞的生物标志物.高表达HER2的肿瘤往往预后不良.HER2分子影像主要是利用放射性核素、磁性材料、发光物质等标记配体能与HER2特异性结合的特性,对患者体内HER2高表达病灶进行显像,从而协助HER2阳性疾病的诊断,筛选出抗HER2治疗有效的患者,并可用于疗效评估,是近年来肿瘤精准医疗研究的热点之一. Human epidermal growth factor receptor-2 (HER2) is a kind of transmembrane receptor with tyrosine kinase activity,and also is a biomarker highly expressed in various cancer cells,often indicating poor clinical prognosis.HER2 expression molecular imaging mainly utilizes the labeled-ligands' ability of specific binding with HER2,such as radionuclide,magnetic materials and fluorescent substances,by which the high-HER2 expressed lesions are shown.This technique provides a strong support for diagnosing HER2-expressed diseases,selecting patients who are respondent to HER2-targeted therapy and evaluating the therapeutic effect,and has become one of the hot spots in the research of precise treatment of tumors in recent years.
出处 《国际放射医学核医学杂志》 2016年第5期363-373,共11页 International Journal of Radiation Medicine and Nuclear Medicine
基金 国家自然科学基金重点项目(31630049)
关键词 人表皮生长因子受体2 分子探针 抗体 单克隆 分子显像 纳米抗体 Human epidermal growth factor receptor-2 Molecular probe Antibodies, monoclonal Molecular imaging Nanobody
  • 相关文献

参考文献9

二级参考文献113

  • 1陈杰 刘彤华 等.人肺癌细胞中生长因子的自泌循环和癌基因表达[J].中华病理学杂志,1995,24:25-28.
  • 2Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD 1839) in chemotherapy resistant non-small-cell lung cancer[J].Int J Cancer, 2005 (113):109-115.
  • 3Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer [J]. J Clin Oncol, 2003,21:2787-2799.
  • 4Zaczek A, Brandt B, Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches [J]. Histol Histopathol, 2005,20(3 ) : 1005-1015.
  • 5Anido J, Matar P, Albanell J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells [J]. Clin Cancer Res, 2003(9) : 1274-1283.
  • 6Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non- small cell lung cancer cell lines [J]. Proc Natl Acad Sci USA, 2005 (102) : 3788-3793.
  • 7Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].Science, 2007(5827): 1039- 1043.
  • 8Hirata A, Hosoi F, Miyagawa M, et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/ HER3 heterodimer formation in lung cancer cells [J]. Cancer Res, 2005,65 (10) : 4253-4260.
  • 9Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to Gefitinib therapy [J]. Science, 2004,304(5676): 1497-1450.
  • 10Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib [J]. N Eng J Med, 2004,350(21 ) :2129-2139.

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部